World Library  
Flag as Inappropriate
Email this Article

Primary biliary cirrhosis

Article Id: WHEBN0000697339
Reproduction Date:

Title: Primary biliary cirrhosis  
Author: World Heritage Encyclopedia
Language: English
Subject: Anti-nuclear antibody, Autoantibody, Cholestasis, Vitamin K, Autoimmune hepatitis
Collection: Autoimmune Diseases, Biliary Tract Disorders, Diseases of Liver, Hepatology
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Primary biliary cirrhosis

Primary biliary cirrhosis
Micrograph of PBC showing bile duct inflammation and injury. H&E stain.
Classification and external resources
Specialty Gastroenterology
ICD-10 K74.3
ICD-9-CM 571.6
OMIM 109720
DiseasesDB 10615
MedlinePlus 000282
eMedicine med/223
MeSH D008105

Primary biliary cirrhosis, also known as primary biliary cholangitis (PBC), is an [8] Use of the new name was advocated in the medical literature in September 2015.[9]

Contents

  • Signs and symptoms 1
  • Causes 2
  • Diagnosis 3
    • Biopsy 3.1
    • Stages 3.2
  • Treatment 4
  • Epidemiology 5
  • Prognosis 6
  • History 7
  • Society and culture 8
    • Support groups 8.1
      • PBC Foundation 8.1.1
      • PBCers 8.1.2
    • Name 8.2
  • References 9
  • External links 10

Signs and symptoms

People with PBC experience fatigue (80%) that leads to sleepiness during the daytime; more half of those have severe fatigue. 20–70% have itching.[10] Those with more severe disease may have jaundice (yellowing of the eyes and skin).[10] PBC impairs bone density and there is an increased risk of fracture.[10] Xanthelasma (skin lesions around the eyes) or other xanthoma may be present as a result of increased cholesterol levels.[11]

PBC can eventually progress to cirrhosis of the liver. This in turn may lead to a number of symptoms or complications:

People with PBC may have the findings of an associated extrahepatic autoimmune disorder such as rheumatoid arthritis or Sjögren's syndrome (in up to 80% of cases).[11][12]

Causes

The cause of the disease is attributed to an immunological basis for the disease, making it an autoimmune disorder.[13] Most of the patients (>90%) have anti-mitochondrial antibodies (AMAs) against pyruvate dehydrogenase complex (PDC-E2), an enzyme complex that is found in the mitochondria.[1]

Many PBC patients have a concomitant autoimmune disease, including rheumatological, endocrinological, gastrointestinal, pulmonary, or dermatological conditions, which suggests shared genetic and immune abnormalities.[12] Common associations include Sjögren's syndrome, systemic sclerosis, rheumatoid arthritis, SLE, hypothyroidism and gluten sensitive enteropathy.[12][14][15][16] In some cases of disease, protein expression may cause an immune tolerance failure, as might be the case with gp210 and p62, nuclear pore proteins. Gp210 has increased expression in the bile duct of anti-gp210 positive patients.[17] Both proteins appear to be prognostic of liver failure relative to anti-mitochondrial antibodies.

A genetic predisposition to disease has been thought important for some time, as evident by cases of PBC in family members, concordance in identical twins, and clustering of autoimmune diseases.[13] In 2009, a Canadian-led group of investigators reported in the New England Journal of Medicine results from the first PBC genome-wide association study.[18][19] This research revealed parts of the IL12 signaling cascade, particularly IL12A and IL12RB2 polymorphisms, to be important in the etiology of the disease in addition to the HLA region. In 2012, two independent PBC association studies increased the total number of genomic regions associated to 26, implicating many genes involved in cytokine regulation such as TYK2, SH2B3 and TNFSF11.[20][21]

In 2003 it was reported that an environmental Gram negative alphabacterium — Novosphingobium aromaticivorans[22] was strongly associated with this disease. Subsequent reports appear to have confirmed this finding suggesting an aetiological role for this organism.[23][24][25] The mechanism appears to be a cross reaction between the proteins of the bacterium and the mitochondrial proteins of the liver cells.[26] The gene encoding CD101 may also play a role in host susceptibility to this disease.[27]

Diagnosis

Immunofluorescence staining pattern of sp100 antibodies (nuclear dots) and AMA.

To diagnose PBC, it needs to be distinguished from other conditions with similar symptoms, such as autoimmune hepatitis or primary sclerosing cholangitis (PSC).

Antinuclear antibody (ANA) are not diagnostic (as they are not specific) but are have a role in prognosis.
Anti-glycoprotein-210 antibodies, and to a lesser degree anti-p62 antibodies, correlate with the disease's progression toward end stage liver failure. Anti-gp210 antibodies are found in 47% of PBC patients.[28][29]
Anti-centromere antibodies often correlate with developing portal hypertension.[30]
Anti-np62[31] and anti-sp100 are also found in association with PBC.

Most patients can be diagnosed without invasive investigation, as the combination of anti-mitochondrial antibodies and typical (cholestatic) liver enzyme tests are considered diagnostic. However, a liver biopsy is needed to determine the stage of disease.

Intermediate magnification micrograph of PBC showing bile duct inflammation and periductal granulomas. Liver biopsy. H&E stain.

Biopsy

PBC is characterized by interlobular bile duct destruction. Histopathologic findings of primary biliary cholangitis include the following:[32]

Stages

  • Stage 1 — Portal Stage: Normal sized triads; portal inflammation, subtle bile duct damage. Granulomas are often detected in this stage.
  • Stage 2 — Periportal Stage: Enlarged triads; periportal fibrosis and/or inflammation. Typically characterized by the finding of a proliferation of small bile ducts.
  • Stage 3 — Septal Stage: Active and/or passive fibrous septa.
  • Stage 4 — Biliary Cirrhosis: Nodules present; garland or jigsaw puzzle pattern.

Treatment

There is no known cure, but medication may slow the progression so that a normal lifespan and quality of life may be attainable for many patients.[11][33][34]

  • Ursodeoxycholic acid (Ursodiol) is the most frequently used treatment. This helps reduce the cholestasis and improves blood test results (liver function tests). It has a minimal effect on symptoms and whether it improves prognosis is controversial.[35][11]
  • To relieve itching caused by bile acids in circulation, which would normally be removed by the liver, cholestyramine (a bile acid sequestrant) may be prescribed to absorb bile acids in the gut and be eliminated, rather than re-enter the blood stream. Alternative agents include stanozolol, naltrexone and rifampicin.[33][34][36]
  • Specific treatment for fatigue, which may be debilitating in some patients, is limited and undergoing trials.[37] Some studies indicate that Provigil (modafinil) may be effective without damaging the liver.[38] Though off-patent, the limiting factor in the use of modafinil in the U.S. is cost. The manufacturer, Cephalon, has made agreements with manufacturers of generic modafinil to provide payments in exchange for delaying their sale of modafinil.[39] The FTC has filed suit against Cephalon alleging anti-competitive behavior.[40]
  • Patients with PBC have poor lipid-dependent absorption of Vitamins A, D, E, K.[41] Appropriate supplementation is recommended when bilirubin is elevated.[11]
  • Patients with PBC are at elevated risk of developing osteoporosis[42] and esophageal varices[43] as compared to the general population and others with liver disease. Screening and treatment of these complications is an important part of the management of PBC.

As in all liver diseases, consumption of alcohol is contraindicated.

In advanced cases, a liver transplant, if successful, results in a favorable prognosis.[44][45]

The farnesoid X receptor agonist, obeticholic acid, which is a modified bile acid, is in phase III clinical trials for PBC.[46]

Epidemiology

PBC is a chronic autoimmune liver disease with a female gender predominance with female:male ratio is at least 9:1 and a peak incidence in the fifth decade of life.[1][47] In some areas of the US and UK the prevalence is estimated to be as high as 1 in 4000. This is much more common than in South America or Africa, which may be due to better recognition in the US and UK.[5][6] First-degree relatives may have as much as a 500 times increase in prevalence, but there is debate if this risk is greater in the same generation relatives or the one that follows.

Prognosis

The serum bilirubin level is an indicator of the prognosis of PBC, with levels of 2–6 mg/dL having a mean survival time of 4.1 years, 6–10 mg/dL having 2.1 years and those above 10 mg/dL having a mean survival time of 1.4 years.[48]

After liver transplant, the recurrence rate may be as high as 18% at 5 years, and up to 30% at 10 years. There is no consensus on risk factors for recurrence of the disease.[49]

Patients with PBC have an increased risk of hepatocellular carcinoma compared to the general population, as is found in other cirrhotic patients. In patients with advanced disease, one series found an incidence of 20% in men and 4% in women.[50]

History

Addison and Gull in 1851 described the clinical picture of progressive obstructive jaundice in the absence of mechanical obstruction of the large bile ducts. Ahrens et al in 1950 coined the term primary biliary cirrhosis for this disease. The association with anti-mitochondrial antibodies was first reported in 1965[51] and their presence was recognized as a marker of early, pre-cirrhotic disease.[52]

Society and culture

Support groups

PBC Foundation

The PBC Foundation is a UK-based international charity offering support and information to people with PBC, their families and friends.[53] It campaigns for increasing recognition of the disorder, improved diagnosis and treatments, and estimates over 8000 people are undiagnosed in the UK.[54][55] The Foundation has supported research into PBC including the development of the PBC-40 [8][59]

PBCers

The PBCers is a US-based patient support group that was founded in 1996 and advocates for greater awareness of the disease and new treatments.[60] It has supported the initiative for a change in name.[8]

Name

In 2014 the PBC Foundation, with the support of the PBCers, the PBC Society (Canada)[61] and other patient groups, advocated a change in name from "primary biliary cirrhosis" to "primary biliary cholangitis", citing that most PBC patients did not have [8][62] Patient and professional groups were canvassed.[63] Support for this name change came from professional bodies including the American Association for the Study of Liver Diseases[64] and the European Association for the Study of the Liver.[65] Advocates for the name change published calls to adopt the new name in multiple hepatology journals in the fall of 2015.[63][9][65][66]

References

  1. ^ a b c d Poupon R (2010). "Primary biliary cirrhosis: a 2010 update". J. Hepatol. 52 (5): 745–58.  
  2. ^ Hirschfield GM, Gershwin ME (Jan 2013). "The immunobiology and pathophysiology of primary biliary cirrhosis". Annual Review of Pathology 8: 303–30.  
  3. ^ Dancygier, Henryk (2010). Clinical Hepatology Principles and Practice of. Springer. pp. 895–.  
  4. ^ Saxena R, Theise N (Feb 2004). "Canals of Hering: recent insights and current knowledge". Seminars in Liver Disease 24 (1): 43–8.  
  5. ^ a b Boonstra K, Beuers U, Ponsioen CY (2012). "Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review". J. Hepatol. 56 (5): 1181–8.  
  6. ^ a b James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV (1999). "Primary biliary cirrhosis once rare, now common in the United Kingdom?". Hepatology 30 (2): 390–4.  
  7. ^ a b c PBC Foundation (UK). "PBC Name Change Press Release". Retrieved 8 July 2015. 
  8. ^ a b c d PBCers Organization. "Primary Biliary Cirrhosis Name Change Initiative" (PDF). 
  9. ^ a b Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R (2015). "Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'". Hepatology.  
  10. ^ a b c Selmi C, Bowlus CL, Gershwin LE, Coppel RL (7 May 2011). "Primary biliary cirrhosis". Lancet 377: 1600–1609.  
  11. ^ a b c d e f g Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ (Jul 2009). "Primary biliary cirrhosis". Hepatology 50 (1): 291–308.  
  12. ^ a b c Floreani A, Franceschet I, Cazzagon N (Aug 2014). "Primary biliary cirrhosis: overlaps with other autoimmune disorders". Seminars in Liver Disease 34 (3): 352–60.  
  13. ^ a b Webb GJ, Siminovitch KA, Hirschfield GM (2015). "The immunogenetics of primary biliary cirrhosis: A comprehensive review.". J Autoimmun.  
  14. ^ Watt FE, James OF, Jones DE (Jul 2004). "Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study". Qjm 97 (7): 397–406.  
  15. ^ Logan RF, Ferguson A, Finlayson ND, Weir DG (Feb 1978). "Primary biliary cirrhosis and coeliac disease: an association?". Lancet 1 (8058): 230–3.  
  16. ^ Volta U, Rodrigo L, Granito A, Petrolini N, Muratori P, Muratori L, et al. (Oct 2002). "Celiac disease in autoimmune cholestatic liver disorders". The American Journal of Gastroenterology 97 (10): 2609–13.  
  17. ^ Nakamura M, Takii Y, Ito M, Komori A, Yokoyama T, Shimizu-Yoshida Y, et al. (Mar 2006). "Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis". Journal of Autoimmunity 26 (2): 138–45.  
  18. ^ Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. (Jun 2009). "Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants". The New England Journal of Medicine 360 (24): 2544–55.  
  19. ^ http://www.uk-pbc.com
  20. ^ a b Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, et al. (Oct 2012). "Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis". Nature Genetics 44 (10): 1137–41.  
  21. ^ Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, et al. (Dec 2012). "Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants". Human Molecular Genetics 21 (23): 5209–21.  
  22. ^ Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, et al. (Nov 2003). "Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium". Hepatology 38 (5): 1250–7.  
  23. ^ Mohammed JP, Mattner J (Jul 2009). "Autoimmune disease triggered by infection with alphaproteobacteria". Expert Review of Clinical Immunology 5 (4): 369–379.  
  24. ^ Kaplan MM (Nov 2004). "Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis". The American Journal of Gastroenterology 99 (11): 2147–9.  
  25. ^ Selmi C, Gershwin ME (Jul 2004). "Bacteria and human autoimmunity: the case of primary biliary cirrhosis". Current Opinion in Rheumatology 16 (4): 406–10.  
  26. ^ Mattner J, Savage PB, Leung P, Oertelt SS, Wang V, Trivedi O, et al. (May 2008). "Liver autoimmunity triggered by microbial activation of natural killer T cells". Cell Host & Microbe 3 (5): 304–15.  
  27. ^ Mohammed JP, Fusakio ME, Rainbow DB, Moule C, Fraser HI, Clark J, et al. (Jul 2011). "Identification of Cd101 as a susceptibility gene for Novosphingobium aromaticivorans-induced liver autoimmunity". Journal of Immunology 187 (1): 337–49.  
  28. ^ Nickowitz RE, Worman HJ (1993). "Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210". J. Exp. Med. 178 (6): 2237–42.  
  29. ^ Bauer A, Habior A (2007). "Measurement of gp210 autoantibodies in sera of patients with primary biliary cirrhosis". J. Clin. Lab. Anal. 21 (4): 227–31.  
  30. ^ Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. (Jan 2007). "Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis". Hepatology 45 (1): 118–27.  
  31. ^ Nesher G, Margalit R, Ashkenazi YJ (Apr 2001). "Anti-nuclear envelope antibodies: Clinical associations". Seminars in Arthritis and Rheumatism 30 (5): 313–20.  
  32. ^ Nakanuma Y, Tsuneyama K, Sasaki M, Harada K (Aug 2000). "Destruction of bile ducts in primary biliary cirrhosis". Baillière's Best Practice & Research. Clinical Gastroenterology 14 (4): 549–70.  
  33. ^ a b Levy C, Lindor KD (Apr 2003). "Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis". Current Treatment Options in Gastroenterology 6 (2): 93–103.  
  34. ^ a b Oo YH, Neuberger J (2004). "Options for treatment of primary biliary cirrhosis". Drugs 64 (20): 2261–71.  
  35. ^ Gluud C, Christensen E (2002). "Ursodeoxycholic acid for primary biliary cirrhosis". The Cochrane Database of Systematic Reviews (1): CD000551.  
  36. ^ Walt RP, Daneshmend TK, Fellows IW, Toghill PJ (Feb 1988). "Effect of stanozolol on itching in primary biliary cirrhosis". British Medical Journal 296 (6622): 607.  
  37. ^ Abbas G, Jorgensen RA, Lindor KD (Jun 2010). "Fatigue in primary biliary cirrhosis". Nature Reviews. Gastroenterology & Hepatology 7 (6): 313–9.  
  38. ^ Modafinil#Primary biliary cirrhosis
    Ian Gan S, de Jongh M, Kaplan MM (Oct 2009). "Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience". Digestive Diseases and Sciences 54 (10): 2242–6.  

    Kumagi T, Heathcote EJ (2008). "Primary biliary cirrhosis". Orphanet Journal of Rare Diseases 3: 1.  
    Jones DE, Newton JL (Feb 2007). "An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis". Alimentary Pharmacology & Therapeutics 25 (4): 471–6.
     
  39. ^ Modafinil#Patent protection and antitrust litigation
    Carrier MA (2011). "Provigil: A Case Study of Anticompetitive Behavior" (PDF). Hastings Science & Technology Law Journal 3 (2): 441–452. 
  40. ^ "Cephalon, Inc." (PDF). Federal Trade Commission. 
  41. ^ Bacon BR, O'Grady JG (2006). Comprehensive clinical hepatology. Elsevier Health Sciences. pp. 283–.  
  42. ^ Collier JD, Ninkovic M, Compston JE (Feb 2002). "Guidelines on the management of osteoporosis associated with chronic liver disease". Gut. 50 Suppl 1 (Suppl 1): i1–9.  
  43. ^ Ali AH, Sinakos E, Silveira MG, Jorgensen RA, Angulo P, Lindor KD (Aug 2011). "Varices in early histological stage primary biliary cirrhosis". Journal of Clinical Gastroenterology 45 (7): e66–71.  
  44. ^ Clavien PA, Killenberg PG (2006). Medical Care of the Liver Transplant Patient: Total Pre-, Intra- and Post-Operative Management. Wiley-Blackwell. p. 155.  
  45. ^ Kaneko J, Sugawara Y, Tamura S, Aoki T, Hasegawa K, Yamashiki N, et al. (Jan 2012). "Long-term outcome of living donor liver transplantation for primary biliary cirrhosis". Transplant International 25 (1): 7–12.  
  46. ^ Ali AH, Carey EJ, Lindor KD (Jan 2015). "Recent advances in the development of farnesoid X receptor agonists". Annals of Translational Medicine 3 (1): 5.  
  47. ^ Weinmann A, Sattler T, Unold HP, Grambihler A, Teufel A, Koch S, et al. (2014). "Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients". Journal of Clinical Gastroenterology 49 (5): 438–47.  
  48. ^ Primary Biliary Cirrhosis~followup at eMedicine
  49. ^ Clavien & Killenberg 2006, p. 429
  50. ^ Jones DE, Metcalf JV, Collier JD, Bassendine MF, James OF (Nov 1997). "Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes". Hepatology 26 (5): 1138–42.  
  51. ^ Walker JG, Doniach D, Roitt IM, Sherlock S (Apr 1965). "Serological tests in diagnosis of primary biliary cirrhosis". Lancet 1 (7390): 827–31.  
  52. ^ Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, et al. (1986). "Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?". Hepatology 6 (6): 1279–84.  
  53. ^ Association of Medical Research Charities. "The PBC Foundation". Retrieved 12 July 2015. 
  54. ^ a b Staff of The Scotsman, January 3, 2008. Dealing with a silent killer
  55. ^ Thain, Collette (2015). "Primary biliary cirrhosis: getting a diagnosis" (online). At Home Magazine. Retrieved 28 July 2015. 
  56. ^ Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James OF, Jones DE (Nov 2005). "Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis". Gut 54 (11): 1622–9.  
  57. ^ Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, et al. (Apr 2011). "Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis". Nature Genetics 43 (4): 329–32.  
  58. ^ Barry Gordon for The Scotsman. 31 December 2003 A royal seal of approval
  59. ^ PBC Foundation. "EASL Name Change Presentation". Retrieved 8 July 2015. 
  60. ^ Kim, Margot. "New hope for PBC liver disease". ABC30 Action news. Retrieved 4 August 2015. 
  61. ^ Cheung AC, Montano-Loza A, Swain M, Vincent C, Renner E, Sherman M, Janssen H, Mason AL (2015). "Time to make the change from 'primary biliary cirrhosis' to 'primary biliary cholangitis'". Can J Gastroenterol Hepatol 29 (6): 293.  
  62. ^ PBC Foundation. "EASL Name Change Presentation". Retrieved 8 July 2015. 
  63. ^ a b Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R (2015). "Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'". Gut.  
  64. ^ AASLD. "A name change for PBC: cholangitis replacing cirrhosis". Retrieved 6 July 2015. 
  65. ^ a b Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R (2015). "Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'". J. Hepatol.  
  66. ^ Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R (2015). "Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'". Gastroenterology.  

External links

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.